Premium
Expression of fibroblast growth factor 23 by canine soft tissue sarcomas
Author(s) -
Hardcastle M. R.,
Dittmer K. E.
Publication year - 2016
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12105
Subject(s) - fibroblast growth factor 23 , mesenchymal stem cell , osteomalacia , pathology , fibroblast , lymph node , growth factor , soft tissue , sarcoma , basic fibroblast growth factor , alveolar soft part sarcoma , biology , cancer research , medicine , cell culture , osteoporosis , parathyroid hormone , receptor , genetics , calcium
Abstract Tumour‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome of humans. Some mesenchymal tumours (often resembling haemangiopericytomas) express molecules that normally regulate phosphorus metabolism; most frequently, fibroblast growth factor 23. Patients develop renal phosphate wasting and inappropriately low serum concentrations of 1, 25 (OH) 2 vitamin D 3 , leading to osteomalacia. Surgical removal of the tumour is curative. The authors examined expression of canine fibroblast growth factor 23 in 49 soft tissue sarcomas, and control tissues from normal adult dogs. RNA extracted from bone or formalin‐fixed, paraffin‐embedded tissues was analysed by end point and quantitative reverse transcriptase‐polymerase chain reaction. Fibroblast growth factor 23 expression was detected in bone, lung, kidney, lymph node and thymus. Fifteen of 49 sarcomas (31%) expressed fibroblast growth factor 23, three of these had high relative expression and some features resembling phosphatonin‐expressing mesenchymal tumours of humans. Further work is required to determine whether TIO may occur in dogs.